2025年改革的目标是340B方案监督、回扣模式和在法律和政策挑战面前的付款准确性。 2025 reforms target 340B program oversight, rebate models, and payment accuracy amid legal and policy challenges.

340B药物定价方案在2025年面临持续的审查和改革努力,参议院帮助委员会强调业务问题,建议加强报告和监督。 The 340B Drug Pricing Program faces ongoing scrutiny and reform efforts in 2025, with the Senate HELP Committee highlighting operational issues and recommending stronger reporting and oversight. HRSA发起了一个自愿的340B回扣示范试点方案,使制造商能够根据Medicare的价格谈判计划向药品提供售后回扣,而不是预付折扣,计划在2025年9月15日前完成,并定于2026年1月1日实施。 HRSA launched a voluntary 340B Rebate Model Pilot Program allowing manufacturers to offer post-sale rebates instead of upfront discounts for drugs under Medicare’s price negotiation program, with plans due by September 15, 2025, and implementation set for January 1, 2026. 这一转变的目的是根据《减少通货膨胀法》防止重复提供折扣。 This shift aims to prevent duplicate discounts under the Inflation Reduction Act. 同时,CMS提议加速收回向340B医院多付的款项,并进行药物购置成本调查,以支持今后的付款调整。 Meanwhile, CMS proposed accelerating clawbacks of overpayments to 340B hospitals and conducting a drug acquisition cost survey to support future payment adjustments. 保护340B实体使用合同药房的州“药品使用权”法律继续发生法律斗争, Legal battles continue over state "pharmacy access" laws that protect 340B entities’ use of contract pharmacies, with mixed court rulings. 《降低通货膨胀法》继续以新的成本上限、补贴和扩大药物谈判来重塑《医疗保健计划》D部分,而菲律宾药品管理局则对创新受到的监管威胁加以反击。 The Inflation Reduction Act continues to reshape Medicare Part D with new cost caps, subsidies, and expanded drug negotiations, while PhRMA pushes back against perceived regulatory threats to innovation.